Consun has grown from a focused nephrology player into a diversified pharmaceutical group through disciplined execution and innovation.
Founding of predecessor entity; entry into nephrology TCM with the development of Uremic Clearance Granules.
Modern GMP production lines completed; marketing network expanded across South China.
Portfolio expanded into imaging contrast agents with Gadopentetic Acid Injection.
Multi-therapy expansion into GYN, orthopedics and dermatology; Kidney Repair Granules approved.
Main Board listing on the Hong Kong Stock Exchange (01681).
Strategic acquisition of Yulin Pharmaceutical — classic brands including Zhenggu Shui.
Inner Mongolia manufacturing site operational; northern market coverage strengthened.
Innovative pipeline assets SK-08, SK-09 advance to clinical stages; Iopamidol passes consistency evaluation.
Inclusion in Stock Connect; enhanced ESG management framework.